Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018(Open Access)
机构：[1]Department of Neurology, Xiangya Hospital, Central South University, Changsha, China,[2]Department of Neurology, PekingUnion Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,[3]Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, China,[4]Department ofNeurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China,[5]Department of Neurology, The SecondAffiliated Hospital, Harbin Medical University, Harbin, China,[6]Department of Neurology, West China Hospital, SichuanUniversity, Chengdu, China,四川大学华西医院[7]Department of Neurology, The First Affiliated Hospital of Shanxi Medical University, Taiyuan,China,[8]Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China,重庆医科大学附属第一医院[9]Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China,[10]Departmentof Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China,首都医科大学附属天坛医院[11]Department of Neurology, Beijing TongrenHospital, Capital Medical University, Beijing, China,首都医科大学附属同仁医院[12]Department of Neurology, The First Affiliated Hospital of WenzhouMedical University, Wenzhou, China,[13]Department of Neurology, Peking University First Hospital, Beijing, China,[14]Department of Neurology, Tianjin Medical University General Hospital, Tianjin, China,[15]Department of Neurology, TongjiHospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,华中科技大学同济医学院附属同济医院[16]Department ofNeurology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China,[17]Department of Neurology, XuanwuHospital, Capital Medical University, Beijing, China,首都医科大学宣武医院[18]Department of Neurology, The First Affiliated Hospital of Fujian MedicalUniversity, Fuzhou, China,[19]Department of Neurology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou,China,中山大学附属第一医院[20]Department of Neurology, General Hospital of the People’s Liberation Army, Beijing, China,[21]Department ofNeurology, The Second Hospital of Lanzhou University, Lanzhou, China,[22]Department of Neurology, The First AffiliatedHospital, Guangxi Medical University, Nanning, China,[23]Department of Neurology, Nanfang Hospital, Southern MedicalUniversity, Guangzhou, China,[24]Department of Neurology, The Second Affiliated Hospital of Guangzhou Medical University,Guangzhou, China,[25]Department of Neurology, The First Affiliated Hospital, Dalian Medical University, Dalian, China,大连医科大学附属第一医院[26]Department of Neurology, Affiliated Zhongshan Hospital, Xiamen University, Xiamen, China
The authors thank the following neurologist professors for sharing information about patients with multiple sclerosis in their clinics: Wenyu Li (Department of Neurology, Sir Run Jinn Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China), Qun Xue (Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, China), Daowen Chen (Department of Neurology, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China), Xueping Zheng (Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China), Lei Li (Department of Neurology, The Second Affiliated Hospital, Harbin Medical University, Harbin, China), Yinxi Zhang (Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China), Le Fang (Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China), Jialu Huang (Department of Neurology, Southwest Hospital, Third Military Medical University, Chongqing, China), Yangtai Guan (Department of Neurology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China), Xiaoli Yao (Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China), Hui Liang (Department of Neurology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China), Dehui Huang (Department of Neurology, Chinese PLA General Hospital, Beijing, China), Zhe Wu (Department of Neurology, First Affiliated Hospital, China Medical University, Shenyang, China), and Li Guo (Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, China). We also acknowledge medical writing assistance provided by Ms. Sunita Rana and Dr. Kaushik Subramanian, Indegene Pvt. Ltd., Bengaluru, India. Funding. This study was supported by the grants from the National Natural Science Foundation of China (Grant Numbers: 81801203 and 81771364) and the Natural Science Foundation of Hunan Province (Grant Number: 2019JJ50973).
第一作者机构：[1]Department of Neurology, Xiangya Hospital, Central South University, Changsha, China,
通讯作者：
推荐引用方式(GB/T 7714)：
Ran Zhou,Qiuming Zeng,Huan Yang,et al.Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018(Open Access)[J].FRONTIERS IN NEUROLOGY.2021,12:doi:10.3389/fneur.2021.651511.
APA：
Ran Zhou,Qiuming Zeng,Huan Yang,Yan Xu,Guojun Tan...&Weihong Zheng.(2021).Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018(Open Access).FRONTIERS IN NEUROLOGY,12,
MLA：
Ran Zhou,et al."Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018(Open Access)".FRONTIERS IN NEUROLOGY 12.(2021)
